Though blockade of programmed cell death receptor 1/programmed cell death receptor ligand 1 (PD1/PDL1) axis with mono-antibody, Pembrolizumab and Nivolumab, has shed light on partial patients, who showed high PDL1 expression in tumors, the overall treating efficacy in advanced CCA patients still needs further observation (3–6). The gene discussed is PDCD1; the disease is cholangiocarcinoma.